• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
By BRET JENSEN
Aug 25, 2017 | 01:30 PM EDT
Stocks quotes in this article: ADMS, FLXN, NEOS, DVAX, MRK, AZN

This commentary originally appeared on Real Money Pro at 11:30 on Aug. 25, 2017. Click here to learn about this dynamic market information service for active traders.

Today, we'll continue our discussion of several small biotech/biopharma names that look attractive heading into key milestone dates in the months ahead. But before we get to some new ideas, it's been a good week for two firms we have recently written about.

Adamas Pharmaceuticals (ADMS) , a name we gave a "thumbs up" to six weeks ago, is up around 45% in Friday morning trading. Just after the bell on Thursday, the FDA gave the green light to the company's primary drug candidate ADS -5102. The compound became the first approved to treat Levodopa-induced Dyskinesia found in Parkinson's patients.

This condition is found in the vast majority of the Parkinson's population and should find a potential market of 150,000 to 200,000 individuals just in the U.S. We liked Adamas as it approached this critical PDUFA (Prescription Drug User Fee Act) date.

On Wednesday, we highlighted the attractiveness of Flexion Therapeutics (FLXN) in front of its PDUFA date of Oct. 6 for its primary drug candidate Zilretta. Flexion got a boost in Thursday trading when Northland Capital initiated the name as an "Outperform." We obviously still like the prospects for Flexion into its key decision date.

Now on to additional small biotech/biopharmas that look favorable ahead of milestone dates.

A compound called NT-0201 from Neos Therapeutics (NEOS) is up for PDUFA review on Sept. 15. Similar to the other two recently approved drugs in the company's arsenal it is aimed at Attention Deficit Hyperactivity Disorder, or ADHD, which has grown to be an almost $10 billion market in the U.S.

Although NT-0201 probably will only see eventual peak sales of $25 million to $50 million, it can be serviced by the same sales force marketing and distributing the company's two other drugs aimed at the same space. This should boost sales and margins quite efficiently.

With a market cap of around $200 million, Texas-based Neos does not have to garner much of a share in this huge market to be attractive from an investment perspective. The company could also make for an attractive bite-sized acquisition for a larger suitor that wants to expand its footprint in this growing market.

A key date circled on my calendar is Nov. 10. That is when the five-year-old saga Dynavax Technologies (DVAX) has endured to push its hepatitis B vaccine Heplisav-B over the finish line will finally come to an end. The outcome is far from uncertain now after the biologic's Ad Comm Panel voted overwhelmingly to recommend the vaccine for approval.

The extra time between the Ad Comm Panel vote on July 28 to November will allow Dynavax to design the post-marketing study that should formally get the rubber stamp in the second week of November.

Heplisav-B should have at least $500 million peak sales potential of at least $500 million just in the U.S. And I suspect the company is in talks with various vaccine players, such as Merck (MRK) , to license global rights and possibly become a marketing and distribution partner in the U.S.

The company also has a very promising oncology asset -- "SD-101" -- moving to mid-stage development as well as a promising mid-stage asthma compound in development with partner AstraZeneca (AZN) . Even with the stock's recent rally, the shares still look significantly undervalued from a "sum-of-the-parts" valuation.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long ADMS, DVAX, FLXN and NEOS.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login